Genocea to Present at Upcoming Investor Conferences
Genocea Biosciences (Nasdaq: GNCA) announced its senior leadership will present at various conferences in January 2022. Key events include the Longwood Healthcare Leaders Winter Webconference on January 6, addressing innovations in cell therapy, and the LifeSci Partners 11th Annual Corporate Access Event on January 7, discussing oncology cell therapy. Additionally, a corporate update will be delivered at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, followed by participation in Advanced Therapies Week on January 26. Genocea aims to provide life-changing immunotherapies for cancer patients.
- None.
- None.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Conferences:
| Event: | Longwood Healthcare Leaders Winter Webconference - Details |
| Topic 1: | Innovation in Cell Therapy |
| Format: | Panel |
| Date: | Thursday, January 6, 2022 |
| Time: | 1:30 PM ET |
| Topic 2: | Making a Big Impact With Limited Resources |
| Format: Date: Time: | Panel Thursday, January 6, 2022 5:10 PM ET |
Event: | LifeSci Partners 11th Annual Corporate Access Event - Details |
| Topic 1: | Innovative Approaches to Cell Therapy for Oncology |
| Format: | Panel |
| Date: | Friday, January 7, 2022 |
| Time: | 8:30 AM ET |
| Topic 2: | Cancer Vaccines: Promises, Promises … Has Their Day Come? |
| Format: Date: Time: | Panel Friday, January 7, 2022 2:00 PM ET |
| Event: | H.C. Wainwright BIOCONNECT Virtual Conference - Details |
| Topic: | Corporate Update |
| Format: | On demand presentation |
| Date: | Monday, January 10, 2022 |
| Time: | 7:00 AM ET |
| Event: | Advanced Therapies Week - Details |
| Topic: | Add It Up: 3 Things to Consider for Capacity Expansion |
| Format: | Panel |
| Date: | Wednesday, January 26, 2022 |
| Time: | 5:00 PM ET |
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.
| Investor Contact: | Media Contact: | ||
| Dan Ferry | Sarah O’Connell | ||
| 617-430-7576 | soconnell@vergescientific.com | ||
| daniel@lifesciadvisors.com |
FAQ
What events will Genocea Biosciences present at in January 2022?
What topics will be discussed at the Longwood Healthcare Leaders Winter Webconference?
When is the LifeSci Partners 11th Annual Corporate Access Event?
What will be presented at the H.C. Wainwright BIOCONNECT Virtual Conference?
What is Genocea's mission related to cancer treatment?
What is the ATLAS platform used by Genocea?
